LAUSR

TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 2001; 276: 47771–47774. 8 Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112: 2190–2198. 9 Bence KK, Delibegovic M, Xue B, Gorgun CZ, Hotamisligil GS, Neel BG et al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 2006; 12: 917–924. 10 Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995; 269: 1427–1429. 11 Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012; 119: 3539–3549. 12 Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia 2013; 27: 1882–1890. 13 Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest 2014; 124: 2762–2773. 14 Aziz A, Baxter EJ, Edwards C, Cheong CY, Ito M, Bench A et al. Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. J Clin Invest 2013; 123: 2169–2182. 15 Heinrichs S, Conover LF, Bueso-Ramos CE, Kilpivaara O, Stevenson K, Neuberg D et al. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife 2013; 2: e00825.